Leucine 10 allelic variant in signal peptide of PCSK9 increases the LDL cholesterol-lowering effect of statins in patients with familial hypercholesterolaemia

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 22, Issue 10, 2012, Pages 831-835

  Pisciotta, L ^a   Sallo, R ^a   Rabacchi, C ^b   Wunsch, A ^b   Calandra, S ^b   Bertolini, S ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Familial hypercholesterolaemia (FH); LDL cholesterol (LDL C); PCSK9 signal peptide polymorphism; Statins

Indexed keywords

APOLIPOPROTEIN E; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LEUCINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; PCSK9 PROTEIN, HUMAN; SERINE PROTEINASE; SIGNAL PEPTIDE;

ADULT; ALLELE; ARTICLE; BLOOD; DNA SEQUENCE; DRUG EFFECT; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETICS; HOMOZYGOTE; HUMAN; MALE; METABOLISM; MIDDLE AGED; MUTATION; STATISTICAL MODEL;

ADULT; ALLELES; APOLIPOPROTEINS E; CHOLESTEROL, LDL; FEMALE; GENE FREQUENCY; HOMOZYGOTE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPOPROTEINEMIA TYPE II; LEUCINE; LINEAR MODELS; MALE; MIDDLE AGED; MUTATION; POLYMORPHISM, GENETIC; PROPROTEIN CONVERTASES; PROTEIN SORTING SIGNALS; RECEPTORS, LDL; SEQUENCE ANALYSIS, DNA; SERINE ENDOPEPTIDASES;

EID: 84866029049     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.numecd.2011.04.003     Document Type: Article

References (28)

1. Abifadel M., Rabès J.-P., Devillers M., et al. Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease. Hum Mutat 2009, 30:520-529.
2. Mousavi S.A., Berge K.E., Leren T.P. The unique role of proprotein convertase subtilisin/kexin 9 in cholesterol homeostasis. J Intern Med 2009, 266:507-519.
3. Horton J.D., Cohen J.C., Hobbs H.H. PCSK9: a convertase that coordinates LDL catabolism. J Lipid Res 2009, 50:S172-S177.
4. Poirier S., Mayer G., Poupon V., et al. Dissection of the endogenous cellular pathways of PCSK9-induced low density lipoprotein receptor degradation. Evidence for an intracellular route. J Biol Chem 2009, 384:28856-28864.
5. Abifadel M., Rabès J.-P., Jambart S., et al. The molecular basis of familial hypercholesterolemia in Lebanon: spectrum of LDLR mutations and role of PCSK9 as a modifier gene. Hum Mutat 2009, 30:E682-E691.
6. Abifadel M., Bernier L., Dubuc G., et al. A PCSK9 variant and familial combined hyperlipidaemia. J Med Genet 2008, 45:780-786.
7. Chen S.N., Ballantyne C.M., Gotto A.M., Tan Y., Willerson J.T., Marian A.J. A common PCSK9 haplotype, encompassing the E670G coding single nucleotide polymorphism, is a novel genetic marker for plasma low-density lipoprotein cholesterol levels and severity of coronary atherosclerosis. J Am Coll Cardiol 2005, 45:1611-1619.
8. Yue P., Averna M., Lin X., Schonfeld G. The c.43_44insCTG variation in PCSK9 is associated with low plasma LDL-cholesterol in a Caucasian population. Hum Mutat 2006, 27:460-466.
9. Dubuc G., Tremblay M., Paré G., et al. A new method for measuring of total plasma PCSK9: clinical applications. J Lipid Res 2010, 51:140-149.
10. Berge K.E., Ose L., Leren T.P. Missense mutations in the PCSK9 gene are associated with hypocholesterolemia and possibly increased response to statin therapy. Arterioscler Thromb Vasc Biol 2006, 26:1094-1100.
11. Bertolini S., Pisciotta L., Di Scala L., et al. Genetic polymorphisms affecting the phenotypic expression in familial hypercholesterolemia. Atherosclerosis 2004, 174:57-65.
12. Sambrook J., Fritsch E.F., Maniatis T. Molecular cloning: a laboratory manual 1989, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
13. Pisciotta L., Oliva C.P., Cefalu A.B., et al. Additive effect of mutations in LDLR and PCSK9 genes on the phenotype of familial hypercholesterolemia. Atherosclerosis 2006, 186:433-440.
14. Hixson J.E., Vernier D.T. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 1990, 31:545-548.
15. Bertolini S., Cantafora A., Averna M., et al. Clinical expression of familial hypercholesterolemia in clusters of mutations of the LDL receptor gene that cause a receptor-defective or receptor-negative phenotype. Arterioscler Thromb Vasc Biol 2000, 20:e41-e52.
16. Nicholls S.J., Brandrup-Wognsen G., Palmer M., Barter P.J. Meta-analysis of comparative efficacy of increasing dose of Atorvastatin versus Rosuvastatin versus simvastatin on lowering levels of atherogenic lipids (from VOYAGER). Am J Cardiol 2010, 105:69-76.
17. Weng T.-C., Kao Yang Y.-H., Lin S.-J., Tai S.-H. A systematic review and meta-analysis on the therapeutic equivalence of statins. J Clin Pharm Ther 2010, 35:139-151.
18. Miyake Y., Kimura R., Kokubo Y., et al. Genetic variants in PCSK9 in the Japanese population: rare genetic variants in PCSK9 might collectively contribute to plasma LDL cholesterol levels in the general population. Atherosclerosis 2008, 196:29-36.
19. Fasano T., Cefalù A.B., Di Leo E., et al. A novel loss of function mutation of PCSK9 gene in white subjects with low-plasma low-density lipoprotein cholesterol. Arterioscler Thromb Vasc Biol 2007, 27:677-681.
20. Fisher T.S., Lo Surdo P., Pandit S., et al. Effects of pH and low density lipoprotein (LDL) on PCSK9-dependent LDL receptor regulation. J Biol Chem 2007, 282:20502-20512.
21. Scartezini M., Hubbart C., Whittall R.A., Cooper J.A., Neil A.H.W., Humphries S.E. The PCSK9 gene R46L variant is associated with lower plasma lipid levels and cardiovascular risk in healthy U.K. men. Clin Sci 2007, 113:435-441.
22. Folsom A.R., Peacock J.M., Boerwinkle E., Atherosclerosis Risk in Communities (ARIC) Study Investigators Variation in PCSK9, low LDL cholesterol, and risk of peripheral arterial disease. Atherosclerosis 2009, 202:211-215.
23. Benn M., Nordestgaard B.G., Grande P., Schnohr P., Tybiærg-Hansen A. PCSK9 R46L, low-density lipoprotein cholesterol levels, and risk of ischemic heart disease. J Am Coll Cardiol 2010, 55:2833-2842.
24. Strøm T.B., Holla Ø. L., Cameron J., Berge K.E., Leren T.P. Loss-of-function mutation R46L in the PCSK9 gene has little impact on the levels of total serum cholesterol in familial hypercholesterolemia heterozygotes. Clin Chim Acta 2010, 411:229-233.
25. Mega J.L., Morrow D.A., Brown A., Cannon C.P., Sabatine M.S. Identification of genetic variants associated with response to statin therapy. Arterioscler Thromb Vasc Biol 2009, 29:1310-1315.
26. Medina M.W., Krauss R.M. The role of HMGCR alternative splicing in statin efficacy. Trends Cardiovasc Med 2009, 19:173-177.
27. Kajinami K., Brousseau M.E., Ordovas J.M., Schaefer E.J. Interactions between common genetic polymorphisms in ABCG5/G8 and CYP7A1 on LDL cholesterol-lowering response to atorvastatin. Atherosclerosis 2004, 175:287-293.
28. Romaine S.P.R., Bailey K.M., Hall A.S., Balmforth A.J. The influence of SLCO1B1 (OATP1B1) polymorphisms on response to statin therapy. Pharmacogenomics J 2010, 10:1-11.